NeuroVasx wins CE Mark for cPAX aneurysm treatment system

According to NeuroVasx, the cPAX system is a minimally invasive device for the embolization of cerebral aneurysms, abnormal bulges or sacs in the wall of an artery in the brain. If ruptured, aneurysms can result in massive intracranial bleeding and often lead to death.

cPAX is a polymer strand delivered through a microcatheter using the same delivery technique as the currently used platinum coil technology. cPAX was designed to achieve more complete filling of the aneurysm using fewer devices and provide the physician the ability to detach the device at any point versus a fixed detachment zone common to platinum coils, the company said.

Eric Timko, president and CEO of NeuroVasx, said: “We believe that cPAX offers substantial advantages over traditional platinum coils. We look forward to the pending 510(k) clearance of cPAX followed by our initial US commercialization efforts.”